James Ryan - BioNTech Chief Board
BNTX Stock | USD 92.24 2.29 2.55% |
Executive
James Ryan is Chief Board of BioNTech SE
Age | 49 |
Address | An der Goldgrube 12, Mainz, Germany, 55131 |
Phone | 49 6131 9084 0 |
Web | https://www.biontech.de |
James Ryan Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Ryan against BioNTech stock is an integral part of due diligence when investing in BioNTech. James Ryan insider activity provides valuable insight into whether BioNTech is net buyers or sellers over its current business cycle. Note, BioNTech insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioNTech'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Ryan over two months ago Payment of 15970 shares by James Ryan of Gray Television subject to Rule 16b-3 | ||
James Ryan over three months ago Payment of 10936 shares by James Ryan of Gray Television subject to Rule 16b-3 | ||
James Ryan over a year ago Acquisition by James Ryan of 1883 shares of Ballys Corp subject to Rule 16b-3 |
BioNTech Management Efficiency
The company has return on total asset (ROA) of 0.0262 % which means that it generated a profit of $0.0262 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0462 %, meaning that it created $0.0462 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Return On Capital Employed is likely to drop 0.03 in 2024. At this time, BioNTech's Fixed Asset Turnover is fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Debt To Assets are likely to drop 0.01 in 2024.Similar Executives
Found 13 records | EXECUTIVE Age | ||
Carol MBA | Jaguar Animal Health | 60 | |
Philippe Brianceau | Jaguar Animal Health | N/A | |
David Hava | Pulmatrix | 40 | |
John JD | Adial Pharmaceuticals | N/A | |
James Roach | Pulmatrix | N/A | |
Peter Hodge | Jaguar Animal Health | N/A | |
Robert CPA | Acasti Pharma | 52 | |
Bankole Johnson | Adial Pharmaceuticals | 58 | |
David JD | Pulmatrix | 66 | |
Roger Waltzman | Jaguar Animal Health | N/A | |
Brian Groch | Acasti Pharma | N/A | |
Karen Brunke | Jaguar Animal Health | 71 | |
Serge Martinod | Jaguar Animal Health | 57 |
Management Performance
Return On Equity | 0.0462 | ||||
Return On Asset | 0.0262 |
BioNTech SE Leadership Team
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Katalin Kariko, Senior Therapies | ||
Jens Holstein, CFO Board | ||
Sylke Maas, Vice Strategy | ||
Michael Boehler, MD Communications | ||
Siegbert Kloos, Datand Digital | ||
Sierk Poetting, COO MD | ||
Pr MD, CoFounder Board | ||
Zach Taylor, Senior Strategy | ||
Ozlem MD, Chief CoFounder | ||
Sean Marett, Chief Officer | ||
Oliver Henning, Senior Operations | ||
Oliver Hennig, Senior Operations | ||
Ugur MD, CEO CoFounder | ||
James Ryan, Chief Board | ||
Ryan Richardson, MD Officer | ||
Sebastian MD, Senior Research |
BioNTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioNTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0462 | ||||
Return On Asset | 0.0262 | ||||
Profit Margin | 0.24 % | ||||
Operating Margin | 0.40 % | ||||
Current Valuation | 5.05 B | ||||
Shares Outstanding | 240.99 M | ||||
Shares Owned By Insiders | 62.84 % | ||||
Shares Owned By Institutions | 18.26 % | ||||
Number Of Shares Shorted | 3.16 M | ||||
Price To Earning | 5.19 X |
Pair Trading with BioNTech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.Moving together with BioNTech Stock
0.72 | EVOK | Evoke Pharma | PairCorr |
Moving against BioNTech Stock
0.55 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
0.46 | VKTX | Viking Therapeutics | PairCorr |
0.45 | ELYM | Eliem Therapeutics Trending | PairCorr |
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 4.1 | Revenue Per Share 15.873 | Quarterly Revenue Growth (0.65) | Return On Assets 0.0262 |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.